Common Adverse Effects of Anti-HER2 Therapies and Practical Management Recommendations
The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
2 Clarke Drive Cranbury, NJ 08512